- Conditions
- Alzheimer's Disease
- Interventions
- donezepil (Aricept)
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004 – 2007
- U.S. locations
- 2
- States / cities
- New Haven, Connecticut • Albany, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–14
of 14
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Alzheimer's Disease
- Interventions
- Coconut Oil Beverage, Placebo Beverage
- Drug · Other
- Lead sponsor
- University of South Florida
- Other
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Alzheimer's Disease
- Interventions
- No Intervention
- Other
- Lead sponsor
- Eisai Korea Inc.
- Industry
- Eligibility
- 19 Years and older
- Enrollment
- 3,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Nutley, New Jersey
- Conditions
- Mild Cognitive Impairment
- Interventions
- Atomoxetine, Placebo
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Early Alzheimers Disease
- Interventions
- buntanetap/posiphen, Placebo
- Drug
- Lead sponsor
- Annovis Bio Inc.
- Industry
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 760 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 78
- States / cities
- Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 72 more
- Conditions
- Alzheimer's Disease
- Interventions
- Hydroxypropyl Beta Cyclodextrin, Placebo
- Drug
- Lead sponsor
- Cyclo Therapeutics, Inc.
- Industry
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 5
- States / cities
- Brooksville, Florida • Winter Park, Florida • Marrero, Louisiana + 2 more
- Conditions
- Alzheimer Disease, Alzheimer Disease 1, Alzheimer Disease 2, Alzheimer Disease 3, Alzheimer Disease 4, Alzheimer Disease 5, Alzheimer Disease 6, Alzheimer Disease 7, Alzheimer Disease 8, Alzheimer Disease 9, Late-Onset, Alzheimer Disease 10, Alzheimer Disease 11, Alzheimer Disease 12, Alzheimer Disease 13, Alzheimer Disease 14, Alzheimer Disease 15, Alzheimer Disease 16, Alzheimer Disease 17, Alzheimer Disease 18, Alzheimer Disease 19, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Alzheimer Disease Focal
- Interventions
- No Intervention
- Other
- Lead sponsor
- ProgenaBiome
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2030
- U.S. locations
- 1
- States / cities
- Ventura, California
- Conditions
- Alzheimer's Disease
- Interventions
- caprylic triglyceride, long-chain triglyceride
- Drug
- Lead sponsor
- Cerecin
- Industry
- Eligibility
- 55 Years to 85 Years
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- St. Petersburg, Florida
- Conditions
- Alzheimer Disease
- Interventions
- Simufilam 100 mg oral tablet, Placebo
- Drug
- Lead sponsor
- Cassava Sciences, Inc.
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 15
- States / cities
- Gilbert, Arizona • Surprise, Arizona • Imperial, California + 12 more
- Conditions
- Alzheimer Disease
- Interventions
- lecozotan SR (SRA-333)
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 33
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Costa Mesa, California + 30 more
- Conditions
- Alzheimer's Disease, Dementia, Behavioral Symptoms
- Interventions
- Divalproex ER, Quetiapine
- Drug
- Lead sponsor
- University of Cincinnati
- Other
- Eligibility
- 55 Years to 85 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Alzheimer Disease, Alzheimer Disease 1, Alzheimer Disease 2, Alzheimer Disease 3, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Alzheimer Disease 9, Alzheimer Disease 4, Alzheimer Disease 7, Alzheimer Disease 17, Alzheimer's Dementia Late Onset, Alzheimer Disease 5, Alzheimer Disease 6, Alzheimer Disease 8, Alzheimer Disease 10, Alzheimer Disease 11, Alzheimer Disease 12, Alzheimer Disease 13, Alzheimer Disease 14, Alzheimer Disease 15, Alzheimer Disease 16, Alzheimer Disease 18, Alzheimer Disease 19, Dementia, Dementia Alzheimers, Dementia, Mild, Dementia of Alzheimer Type, Dementia Moderate, Dementia Senile, Mild Cognitive Impairment, Mild Dementia, MCI, Cognitive Impairment, Cognitive Decline, Cognitive Impairment, Mild
- Interventions
- Spectris™ AD - Active, Spectris™ AD - Sham
- Device
- Lead sponsor
- Cognito Therapeutics, Inc.
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 673 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 68
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Sun City, Arizona + 62 more
- Conditions
- Alzheimer's Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders
- Interventions
- Donanemab, Placebo, Dexamethasone
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 60 Years to 85 Years
- Enrollment
- 1,175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 43
- States / cities
- Chandler, Arizona • Irvine, California • Long Beach, California + 38 more
- Conditions
- Alzheimer Disease
- Interventions
- BPN14770, BPN14770 placebo, Donepezil, Donepezil placebo, Scopolamine 0.6 MG/ML, Scopolamine placebo
- Drug
- Lead sponsor
- Tetra Discovery Partners
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Austin, Texas